Summary
Edwards Lifesciences Corporation reported solid growth for the second quarter and first half of 2012. Net sales increased by 11.8% and 12.6% for the respective periods, driven significantly by the strong performance of Transcatheter Heart Valves, particularly the Edwards SAPIEN valve following its US launch in late 2011. This segment saw substantial year-over-year growth, contributing significantly to the overall revenue increase. While Surgical Heart Valve Therapy experienced a slight decline in the quarter, it showed modest growth in the first half. Critical Care sales saw a modest decrease. The company demonstrated improved profitability with gross profit margin increasing by 2.7 percentage points in the quarter due to a more favorable product mix and currency hedging benefits, although SG&A and R&D expenses also rose to support growth initiatives and new product development. Financially, the company's cash position improved significantly, with cash and cash equivalents increasing to $304.3 million from $171.2 million at the end of 2011. Operating activities generated strong cash flow, and the company continued its share repurchase program through accelerated share repurchase agreements. Despite ongoing legal proceedings related to intellectual property disputes, management expressed confidence that these matters would not materially impact the company's financial position. The company also reported a material weakness in internal controls related to financial reporting, which is currently under remediation.
Financial Highlights
43 data points| Revenue | $482.00M |
| Cost of Revenue | $129.80M |
| Gross Profit | $352.20M |
| R&D Expenses | $74.00M |
| SG&A Expenses | $182.40M |
| Net Income | $67.80M |
| EPS (Basic) | $0.10 |
| EPS (Diluted) | $0.09 |
| Shares Outstanding (Basic) | 689.40M |
| Shares Outstanding (Diluted) | 710.40M |
Key Highlights
- 1Net sales for Q2 2012 increased 11.8% to $482.0 million, and H1 2012 sales increased 12.6% to $941.2 million.
- 2Transcatheter Heart Valves segment sales surged by 70.8% in Q2 and 69.1% in H1, driven by the US launch of the Edwards SAPIEN valve.
- 3Gross profit margin improved to 73.1% in Q2 2012 from 70.4% in Q2 2011, attributed to a more profitable product mix and currency impacts.
- 4Cash and cash equivalents increased significantly to $304.3 million as of June 30, 2012, from $171.2 million at December 31, 2011.
- 5Net cash provided by operating activities was $116.1 million for H1 2012, an increase from $99.4 million in H1 2011.
- 6The company entered into two Accelerated Share Repurchase (ASR) agreements totaling $104 million in Q2 2012.
- 7A material weakness in internal controls over financial reporting was identified, related to the completeness and timeliness of information impacting financial reporting classifications and disclosures. Remediation efforts are underway.